

Eva Gonzalez Barca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3028791/publications.pdf>

Version: 2024-02-01

153
papers

4,455
citations

134610

34
h-index

134545

62
g-index

161
all docs

161
docs citations

161
times ranked

6529
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 794-801. | 0.5 | 5 |
| 2 | A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. <i>Bone Marrow Transplantation</i> , 2022, 57, 176-182. | 1.3 | 1 |
| 3 | Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1196-1205. | 0.8 | 27 |
| 4 | Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH). <i>Antonie van Leeuwenhoek</i> , 2022, 106, 101-107. | 1.0 | 1 |
| 5 | An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. <i>EJHaem</i> , 2022, 3, 722-733. | 0.4 | 1 |
| 6 | IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. <i>International Journal of Hematology</i> , 2022, , . | 0.7 | 0 |
| 7 | Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , 2021, 100, 1023-1029. | 0.8 | 10 |
| 8 | R-CHOP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥ 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021, 10, 1314-1326. | 1.3 | 13 |
| 9 | The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting. <i>Cancer Reports</i> , 2021, 4, e1358. | 0.6 | 6 |
| 10 | End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290. | 2.5 | 21 |
| 11 | Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). <i>Journal of Clinical Oncology</i> , 2021, 39, 7513-7513. | 0.8 | 6 |
| 12 | Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426. | 1.7 | 81 |
| 13 | Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, , . | 1.7 | 11 |
| 14 | Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183. | 5.8 | 26 |
| 15 | Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4762-4770. | 2.5 | 17 |
| 16 | EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and SÅ©zary syndrome: real-world data in Spanish patients (MICADOS study). <i>European Journal of Cancer</i> , 2021, 156, S29-S30. | 1.3 | 1 |
| 17 | Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , 2021, 192, 1020-1025. | 1.2 | 1 |
| 18 | Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399. | 1.3 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Long-term use of repeated doses of dalbavancin as prophylaxis for recurrent Gram-positive bacteraemic cellulitis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 386-387. | 2.8 | 1 |
| 20 | Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. <i>Leukemia and Lymphoma</i> , 2020, 61, 575-581. | 0.6 | 3 |
| 21 | Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , 2020, 104, 198-206. | 1.1 | 3 |
| 22 | Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75. | 0.9 | 14 |
| 23 | Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5174. | 1.2 | 5 |
| 24 | Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. <i>Blood</i> , 2020, 136, 1-2. | 0.6 | 1 |
| 25 | Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21. | 0.6 | 9 |
| 26 | Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 778-788. | 1.7 | 17 |
| 27 | Insulin-like growth factor levels and chronic lymphocytic leukaemia: results from the MCC Spain and EpiLymphSpain studies. <i>British Journal of Haematology</i> , 2019, 185, 608-612. | 1.2 | 1 |
| 28 | Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091. | 0.6 | 6 |
| 29 | The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357. | 1.4 | 127 |
| 30 | Abstract 4725: Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia. , 2019, , . | | 0 |
| 31 | A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. <i>American Journal of Hematology</i> , 2018, 93, 867-873. | 2.0 | 16 |
| 32 | Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. <i>Cancer Epidemiology</i> , 2018, 52, 106-111. | 0.8 | 7 |
| 33 | Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. <i>Leukemia</i> , 2018, 32, 675-684. | 3.3 | 141 |
| 34 | Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 32383-32399. | 0.8 | 9 |
| 35 | Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. <i>Haematologica</i> , 2018, 103, 1881-1888. | 1.7 | 21 |
| 36 | Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series. <i>Annals of Hematology</i> , 2018, 97, 2417-2424. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | <i>In vitro</i> and <i>in vivo</i> activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. <i>Haematologica</i> , 2018, 103, e537-e540. | 1.7 | 15 |
| 38 | Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind. <i>Blood</i> , 2018, 132, 227-227. | 0.6 | 4 |
| 39 | Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7502-7502. | 0.8 | 21 |
| 40 | Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group. <i>Blood</i> , 2018, 132, 1637-1637. | 0.6 | 0 |
| 41 | Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL. <i>Blood</i> , 2018, 132, 1676-1676. | 0.6 | 0 |
| 42 | Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5383-5383. | 0.6 | 0 |
| 43 | Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. <i>European Journal of Nutrition</i> , 2017, 56, 1123-1133. | 1.8 | 11 |
| 44 | Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Åyears follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646. | 0.8 | 7 |
| 45 | Actualizaci3n del diagn3stico y el tratamiento de la leucemia/linfoma T del adulto. <i>Medicina Cl3nica</i> , 2017, 148, 176-180. | 0.3 | 1 |
| 46 | Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017, 35, 520-527. | 0.8 | 20 |
| 47 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO. <i>Hematological Oncology</i> , 2017, 35, 345-345. | 0.8 | 0 |
| 48 | APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 156-157. | 0.8 | 0 |
| 49 | R-COMP VS R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60ÅYEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP. <i>Hematological Oncology</i> , 2017, 35, 186-187. | 0.8 | 0 |
| 50 | Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series. <i>Hematological Oncology</i> , 2017, 35, 349-350. | 0.8 | 0 |
| 51 | Initial management of primary central nervous system lymphoma in Spain in the last decade. The experience of the <scp>GELTAMO</scp> and <scp>S</scp>panish neuro3oncology groups. <i>Hematological Oncology</i> , 2017, 35, 354-355. | 0.8 | 0 |
| 52 | Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112. | 1.7 | 41 |
| 53 | Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824. | 0.6 | 21 |
| 54 | L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)â€”A single-arm phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7514-7514. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Low-Dose PET/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas. <i>Clinical Medicine Insights Blood Disorders</i> , 2016, 9, CMBD.S38468. | 0.3 | 7 |
| 56 | Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. <i>Oncotarget</i> , 2016, 7, 10174-10181. | 0.8 | 65 |
| 57 | Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. <i>Oncotarget</i> , 2016, 7, 18036-18049. | 0.8 | 26 |
| 58 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from the GELTAMO group. <i>British Journal of Haematology</i> , 2016, 173, 245-252. | 1.2 | 24 |
| 59 | Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. <i>Annals of Hematology</i> , 2016, 95, 893-899. | 0.8 | 10 |
| 60 | Clinicobiological features, treatment and survival of 457 patients with histological Grades 3A and 1 ² follicular lymphoma mostly treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2016, 172, 470-473. | 1.2 | 14 |
| 61 | European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016, 101, e407-e410. | 1.7 | 38 |
| 62 | Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84. | 0.7 | 6 |
| 63 | High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 253-262. | 0.8 | 19 |
| 64 | Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 392 High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo. <i>Blood</i> , 2016, 128, 4201-4201. | 0.6 | 3 |
| 65 | R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo. <i>Blood</i> , 2016, 128, 5387-5387. | 0.6 | 1 |
| 66 | Treatment of Primary Cutaneous Marginal Zone B-Cell Lymphomas with Intralesional Rituximab. <i>Blood</i> , 2016, 128, 1796-1796. | 0.6 | 0 |
| 67 | Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo. <i>Blood</i> , 2016, 128, 1850-1850. | 0.6 | 0 |
| 68 | Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. <i>Blood</i> , 2016, 128, 152-152. | 0.6 | 0 |
| 69 | CD30 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Correlates with Non-GCB Subtype but Does Not Have Prognostic Impact in Patients Treated with First Line R-CHOP/R-CHOP-like. <i>Blood</i> , 2016, 128, 4209-4209. | 0.6 | 2 |
| 70 | HIV-infection impact on clinicobiological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818. | 1.0 | 37 |
| 71 | Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. <i>Infectious Agents and Cancer</i> , 2015, 10, 5. | 1.2 | 2 |
| 72 | Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 ¹⁰ /L monoclonal lymphocytes better identifies subgroups with different outcomes. <i>Annals of Hematology</i> , 2015, 94, 627-632. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | CCR5 δ 32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. <i>Lancet HIV</i> , 2015, 2, e236-e242. | 2.1 | 52 |
| 74 | Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPi Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 398-403. | 0.2 | 6 |
| 75 | The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858. | 0.4 | 15 |
| 76 | Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study. <i>Journal of General Virology</i> , 2015, 96, 2286-2292. | 1.3 | 9 |
| 77 | Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. <i>Journal of Geriatric Oncology</i> , 2015, 6, 353-361. | 0.5 | 51 |
| 78 | An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 1493-1493. | 0.6 | 5 |
| 79 | Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 1510-1510. | 0.6 | 2 |
| 80 | Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study. <i>Blood</i> , 2015, 126, 1508-1508. | 0.6 | 0 |
| 81 | Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis. <i>Blood</i> , 2015, 126, 1514-1514. | 0.6 | 0 |
| 82 | Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center. <i>Blood</i> , 2015, 126, 5087-5087. | 0.6 | 0 |
| 83 | Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. <i>Blood</i> , 2015, 126, 3874-3874. | 0.6 | 0 |
| 84 | Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, 505-510. | 1.7 | 34 |
| 85 | Intensification treatment based on early 18 F-FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. <i>British Journal of Haematology</i> , 2014, 167, 327-336. | 1.2 | 42 |
| 86 | Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. <i>Blood</i> , 2014, 123, 1864-1869. | 0.6 | 30 |
| 87 | Impact of prior rituximab on outcomes of autologous stem cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. <i>British Journal of Haematology</i> , 2014, 164, 668-674. | 1.2 | 14 |
| 88 | Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235. | 1.7 | 69 |
| 89 | Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141. | 1.7 | 2 |
| 90 | Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014, 99, e126-e126. | 1.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718. | 0.6 | 10 |
| 92 | Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 581-591. | 1.1 | 42 |
| 93 | Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 1151-1179. | 0.8 | 22 |
| 94 | MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562. | 1.7 | 196 |
| 95 | Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. <i>Clinical Microbiology and Infection</i> , 2013, 19, 474-479. | 2.8 | 211 |
| 96 | Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. <i>Nuclear Medicine Communications</i> , 2013, 34, 946-952. | 0.5 | 27 |
| 97 | HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 1448-1454. | 0.6 | 23 |
| 98 | Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. <i>Plasmatology</i> , 2013, 6, CMBD.S12713. | 4.0 | 0 |
| 99 | Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe amplification. <i>Epigenomics</i> , 2012, 4, 491-501. | 1.0 | 9 |
| 100 | Antibody Response to Merkel Cell Polyomavirus Associated with Incident Lymphoma in the EpiLymph Caseâ€“Control Study in Spain. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1592-1598. | 1.1 | 13 |
| 101 | Utilidad de la PET-TC en la valoraciÃ³n de la respuesta precoz al tratamiento en el linfoma B difuso de celula grande. Resultados preliminares. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 135-141. | 0.0 | 6 |
| 102 | Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2012, 181, 1879-1888. | 1.9 | 31 |
| 103 | Longâ€“term followâ€“up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. <i>British Journal of Haematology</i> , 2012, 157, 637-639. | 1.2 | 12 |
| 104 | Autologous Stem Cell Transplantation with Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial. <i>Blood</i> , 2012, 120, 1978-1978. | 0.6 | 2 |
| 105 | miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040. | 0.6 | 90 |
| 106 | Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011, 117, 4836-4843. | 0.6 | 280 |
| 107 | High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001. | 1.7 | 100 |
| 108 | Prospective study of clinical and biological prognostic factors at diagnosis in patients with early stage B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 429-435. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. <i>Expert Review of Hematology</i> , 2011, 4, 9-16. | 1.0 | 16 |
| 110 | AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. <i>Blood</i> , 2010, 116, 3023-3032. | 0.6 | 95 |
| 111 | Langerhans cell sarcoma: Response to radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2010, 15, 107-109. | 0.3 | 3 |
| 112 | Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328. | 1.1 | 49 |
| 113 | Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 439-451. | 1.5 | 68 |
| 114 | Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010, 21, 1891-1897. | 0.6 | 12 |
| 115 | Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4578-4584. | 0.8 | 116 |
| 116 | Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. <i>Cancer</i> , 2009, 115, 1892-1898. | 2.0 | 34 |
| 117 | Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. <i>Journal of Clinical Oncology</i> , 2009, 27, 1462-1469. | 0.8 | 189 |
| 118 | Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain. <i>Blood</i> , 2009, 114, 3692-3692. | 0.6 | 2 |
| 119 | Hyper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study. <i>Blood</i> , 2009, 114, 931-931. | 0.6 | 0 |
| 120 | Treatment of Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (ALL/LL). Results of a Single Center. <i>Blood</i> , 2009, 114, 4108-4108. | 0.6 | 14 |
| 121 | High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT). <i>Blood</i> , 2009, 114, 1948-1948. | 0.6 | 0 |
| 122 | All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 254-255. | 0.7 | 8 |
| 123 | Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. <i>British Journal of Haematology</i> , 2008, 140, 411-419. | 1.2 | 107 |
| 124 | Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008, 142, 793-801. | 1.2 | 42 |
| 125 | R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008, 93, 1829-1836. | 1.7 | 158 |
| 126 | Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161. | 3.2 | 117 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Impact of interleukin-10 polymorphisms (1082 and 3575) on the survival of patients with lymphoid neoplasms. <i>Haematologica</i> , 2007, 92, 1475-1481. | 1.7 | 26 |
| 128 | Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. <i>Haematologica</i> , 2007, 92, 1489-1494. | 1.7 | 116 |
| 129 | Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk Patients: An Interim Analysis of an Open-Label Clinical Trial in Spain. On Behalf of GEL/TAMO (Spanish Group of Lymphoma).. <i>Blood</i> , 2007, 110, 3443-3443. | 0.6 | 0 |
| 130 | R-ESHAP as Salvage Therapy for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Spanish GEL-TAMO Multicenter Study.. <i>Blood</i> , 2007, 110, 3438-3438. | 0.6 | 17 |
| 131 | Safety of Intrathecal Liposomal Cytarabine (DepocyteÂ®) Injection Given Prophylactically in Patients with High-Risk Diffuse Large B-Cell Lymphoma: A Report of 22 Patients in Spain.. <i>Blood</i> , 2007, 110, 4459-4459. | 0.6 | 1 |
| 132 | Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. <i>Transplantation</i> , 2006, 82, 1093-1100. | 0.5 | 48 |
| 133 | Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1274-1280. | 2.1 | 121 |
| 134 | Impact of IL-10 Polymorphisms in Survival of Lymphoid Neoplasms.. <i>Blood</i> , 2006, 108, 2382-2382. | 0.6 | 0 |
| 135 | Gastrointestinal Involvement in Mantle Cell Lymphoma (MCL). A Prospective Clinical, Endoscopic, Pathological and Molecular Study.. <i>Blood</i> , 2005, 106, 4665-4665. | 0.6 | 0 |
| 136 | Relationship between Seroresponse to Epstein-Barr Virus and Survival in Patients with Lymphoid Malignancies.. <i>Blood</i> , 2005, 106, 4688-4688. | 0.6 | 0 |
| 137 | Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma.. <i>Blood</i> , 2004, 104, 1390-1390. | 0.6 | 0 |
| 138 | Lack of serological evidence for an association between simian virus 40 and lymphoma. <i>International Journal of Cancer</i> , 2003, 104, 522-524. | 2.3 | 70 |
| 139 | Combined isolation of CD34+ progenitor cells and reduction of B cells from peripheral blood by use of immunomagneticâ€f methods. <i>Transfusion</i> , 2002, 42, 912-920. | 0.8 | 3 |
| 140 | Predisposing Factors and Outcome of Staphylococcus aureus Bacteremia in Neutropenic Patients with Cancer. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001, 20, 117-119. | 1.3 | 54 |
| 141 | Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. <i>Bone Marrow Transplantation</i> , 2000, 26, 1051-1056. | 1.3 | 13 |
| 142 | Serious Complications of Bacteremia Caused by Viridans Streptococci in Neutropenic Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2000, 31, 1126-1130. | 2.9 | 136 |
| 143 | Indolent course as presentation in T-prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 1999, 105, 840-840. | 1.2 | 11 |
| 144 | Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). <i>Bone Marrow Transplantation</i> , 1999, 23, 579-587. | 1.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Prognostic Factors Influencing Mortality in Cancer Patients with Neutropenia and Bacteremia. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 539-544. | 1.3 | 75 |
| 146 | Low-dose subcutaneous interleukin-2 in patients with minimal residual lymphoid neoplasm disease. European Journal of Haematology, 1999, 62, 231-238. | 1.1 | 8 |
| 147 | Noninvasive mechanical ventilation in a patient with respiratory failure after hematopoietic progenitor transplantation. Bone Marrow Transplantation, 1998, 22, 1123-1124. | 1.3 | 5 |
| 148 | Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management?. European Journal of Haematology, 1998, 60, 202-208. | 1.1 | 18 |
| 149 | Fatal Myofascial Necrosis Due to Imipenem-resistant Aeromonas hydrophila. Scandinavian Journal of Infectious Diseases, 1997, 29, 91-92. | 1.5 | 9 |
| 150 | Umbilical cord blood transplantation from unrelated donors in an adult weighing 90 kilograms. Role of immunosuppression in engraftment. Bone Marrow Transplantation, 1997, 20, 333-336. | 1.3 | 11 |
| 151 | Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: Relationship with clinico-prognostic features. Leukemia Research, 1997, 21, 67-73. | 0.4 | 30 |
| 152 | Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases. European Journal of Haematology, 1997, 59, 231-237. | 1.1 | 32 |
| 153 | Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 291-296. | 1.3 | 113 |